Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2021 Aug 12;22(2):82–88. doi: 10.1016/j.clml.2021.08.001

Table 2.

Distress and quality of life scores across time by treatment status (n=64)

Variable Baseline Four months Eight months Twelve months
HADS Total, Mean (SD)
 Active treatment 6.90 (4.86) 3.67 (2.73) 3.00 (4.06) 2.00 (1.00)
 Surveillance 8.06 (6.68) 7.13 (6.43) 7.25 (6.32) 7.58 (6.36)
 Total 7.87 (6.39) 6.67 (6.16) 6.72 (6.21) 7.11 (6.29)
FACT Total, Mean (SD)
 Active treatment 125.82 (18.07) 148.28 (11.42) 137.21 (21.47) 148.17 (11.18)
 Surveillance 134.53 (20.69) 136.20 (22.38) 133.85 (25.42) 132.65 (24.52)
 Total 133.08 (20.40) 137.81 (21.55) 134.29 (24.70) 133.94 (24.00)
FACT Physical, Mean (SD)
 Active treatment 22.90 (4.72) 24.78 (3.19) 23.77 (5.24) 27.67 (0.58)
 Surveillance 26.38 (3.47) 26.23 (3.95) 26.10 (3.88) 26.18 (3.92)
 Total 25.81 (3.88) 26.03 (3.86) 25.81 (4.07) 26.31 (3.78)
FACT Social, Mean (SD)
 Active treatment 18.05 (8.41) 25.25 (3.45) 23.44 (2.44) 23.50 (5.07)
 Surveillance 19.46 (6.61) 19.99 (5.99) 19.43 (6.55) 18.10 (6.58)
 Total 19.23 (6.88) 20.69 (5.97) 19.94 (6.30) 18.55 (6.58)
FACT Emotional, Mean (SD)
 Active treatment 18.80 (3.29) 22.67 (1.37) 20.20 (1.30) 20.00 (2.00)
 Surveillance 16.96 (4.49) 17.72 (4.63) 18.00 (4.29) 17.82 (4.31)
 Total 17.26 (4.34) 18.38 (4.65) 18.28 (4.09) 18.00 (4.20)
FACT Functional, Mean (SD)
 Active treatment 18.17 (7.69) 24.30 (2.74) 19.40 (11.17) 22.00 (5.57)
 Surveillance 21.48 (5.49) 22.19 (5.35) 20.69 (5.85) 20.87 (5.94)
 Total 20.93 (5.96) 22.47 (5.11) 20.52 (6.56) 20.96 (5.85)
FACT Lymphoma, Mean (SD)
 Active treatment 47.90 (5.67) 51.29 (8.73) 50.40 (13.48) 55.00 (3.46)
 Surveillance 49.66 (8.55) 50.08 (8.81) 50.10 (9.31) 49.68 (8.90)
 Total 49.36 (8.13) 50.24 (8.71) 50.14 (9.71) 50.12 (8.68)

Note: This report only uses non-missing values in both variables (pairwise deletion) in the two-way table.